CYP4B1

Across TCGA pan-cancer cohorts, CYP4B1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CYP4B1 data layer compared with 19 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CYP4B1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CYP4B1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

HNSC, LUAD, and LSCC are the cancer types where CYP4B1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.649	0.903	.017	18	view →
LUAD	OS	Median	II,III,IV	0.775	0.471	.011	14	view →
LSCC	OS	Quartile	III,IV	0.980	0.754	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CYP4B1–HNSC (OS)

Open the HNSC breakdown →